Sionna Therapeutics, Inc. (SION)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.60-5.26%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sionna Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.556
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.479
Annual ending 2027-12-31
Revenue	—	2.73M
EPS	—	-2.293

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway to fund operations into 2028	Sionna aims to fund operations into 2028 with its current cash.	Intact	cash runway falls short of funding operations into 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash position declined from approximately $289.9 million in 2026-Q1 to $268.3 million in 2026-Q2. Management consistently expects this cash to fund operations into 2028. The trajectory shows a modest cash decline but aligns with management's runway guidance. Delivery assessment Oct 24, 2026
Manage operating losses and cash burn	Operating losses are managed around -$29.6M in Q1 2026.	Under Pressure	operating losses increase significantly beyond -$30M per quarter	Operating income: $-32.47M FY2026-Q2; GAAP. Published target: Operating losses remain near or below -$30M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-32,470,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f264492f-4e9f-483a-9dc4-391d98f66b06. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3 via restructuring announcement. Operating losses increased from approximately $23.8 million in 2025-Q3 to $32.5 million in 2026-Q2, with net loss rising from $18.1 million in 2025-Q2 to $29.9 million in 2026-Q2. The company implemented a 46% workforce reduction and cost-saving measures to manage losses and extend runway, indicating active efforts to control cash burn. Delivery assessment Oct 24, 2026
Advance pipeline toward revenue generation	A supporting condition in Sionna Therapeutics, Inc.'s published investment case. The stated target is Achieve at least $3M revenue in FY27.	Intact	revenue fails to reach $3M in FY27	Revenue: $0 FY2026-Q2; GAAP. Published target: Achieve at least $3M revenue in FY27. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.29

$-2.79 → $-2.29 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.79	$3,333,333	7 / 10
2026-07-25	$-2.79	$3,333,333	7 / 10
2026-07-26	$-2.83	$3,000,000	7 / 10
2026-07-27	$-2.80	$3,000,000	9 / 10
2026-07-28	$-2.80	$3,000,000	9 / 10
2026-07-29	$-2.80	$3,000,000	9 / 10
2026-07-30	$-2.83	$3,000,000	7 / 10
2026-07-31	$-2.83	$3,000,000	7 / 10
2026-08-01	$-2.83	$3,000,000	7 / 10
2026-08-02	$-2.80	$3,000,000	9 / 10
2026-08-03	$-2.80	$3,000,000	9 / 10
2026-08-04	$-2.80	$3,000,000	9 / 10
2026-08-05	$-2.83	$3,000,000	7 / 10
2026-08-06	$-2.80	$3,000,000	9 / 10
2026-08-08	$-2.83	$3,333,330	9 / 9
2026-08-09	$-2.83	$2,727,273	7 / 10
2026-08-10	$-2.83	$3,333,330	9 / 9
2026-08-12	$-2.53	$0	9 / 10
2026-08-13	$-2.53	$0	9 / 10
2026-08-14	$-2.83	$2,727,273	7 / 10
2026-08-15	$-2.83	$2,727,273	7 / 10
2026-08-16	$-2.83	$2,727,273	7 / 10
2026-08-17	$-2.83	$2,727,273	7 / 10
2026-08-18	$-2.83	$2,727,273	7 / 10
2026-08-19	$-2.83	$2,727,273	7 / 10
2026-08-20	$-2.55	$2,727,273	7 / 10
2026-08-21	$-2.55	$2,727,273	7 / 10
2026-08-22	$-2.55	$2,727,273	7 / 10
2026-08-23	$-2.55	$2,727,273	7 / 10
2026-08-24	$-2.55	$2,727,273	7 / 10
2026-08-25	$-2.55	$2,727,273	7 / 10
2026-08-26	$-2.55	$2,727,273	7 / 10
2026-08-27	$-2.55	$2,727,273	7 / 10
2026-08-28	$-2.55	$2,727,273	7 / 10
2026-08-29	$-2.55	$2,727,273	7 / 10
2026-08-30	$-2.55	$2,727,273	7 / 10
2026-08-31	$-2.55	$2,727,273	7 / 10
2026-09-01	$-2.55	$2,727,273	7 / 10
2026-09-02	$-2.55	$2,727,273	7 / 10
2026-09-03	$-2.55	$2,727,273	7 / 10
2026-09-04	$-2.55	$2,727,273	7 / 10
2026-09-05	$-2.55	$2,727,273	7 / 10
2026-09-06	$-2.55	$2,727,273	7 / 10
2026-09-07	$-2.55	$2,727,273	7 / 10
2026-09-08	$-2.55	$2,727,273	7 / 10
2026-09-09	$-2.55	$2,727,273	7 / 10
2026-09-10	$-2.55	$2,727,273	8 / 10
2026-09-11	$-2.55	$2,727,273	8 / 10
2026-09-12	$-2.55	$2,727,273	8 / 10
2026-09-13	$-2.55	$2,727,273	8 / 10
2026-09-14	$-2.55	$2,727,273	8 / 10
2026-09-15	$-2.55	$2,727,273	8 / 10
2026-09-16	$-2.29	$2,727,273	8 / 10
2026-09-17	$-2.29	$2,727,273	8 / 10
2026-09-18	$-2.29	$2,727,273	8 / 10
2026-09-19	$-2.29	$2,727,273	8 / 10
2026-09-20	$-2.29	$2,727,273	8 / 10
2026-09-21	$-2.29	$2,727,273	8 / 10
2026-09-22	$-2.29	$2,727,273	8 / 10
2026-09-23	$-2.29	$2,727,273	8 / 10
2026-09-24	$-2.29	$2,727,273	8 / 10
2026-09-25	$-2.29	$2,727,273	8 / 10
2026-09-26	$-2.29	$2,727,273	8 / 10
2026-09-27	$-2.29	$2,727,273	8 / 10
2026-09-28	$-2.29	$2,727,273	8 / 10
2026-09-29	$-2.29	$2,727,273	8 / 10
2026-09-30	$-2.29	$2,727,273	8 / 10
2026-10-01	$-2.29	$2,727,273	8 / 10
2026-10-02	$-2.29	$2,727,273	8 / 10
2026-10-03	$-2.29	$2,727,273	8 / 10
2026-10-04	$-2.29	$2,727,273	8 / 10
2026-10-05	$-2.29	$2,727,273	8 / 10
2026-10-06	$-2.29	$2,727,273	8 / 10
2026-10-07	$-2.29	$2,727,273	8 / 10
2026-10-08	$-2.29	$2,727,273	8 / 10
2026-10-09	$-2.29	$2,727,273	8 / 10
2026-10-10	$-2.29	$2,727,273	8 / 10
2026-10-11	$-2.29	$2,727,273	8 / 10
2026-10-12	$-2.29	$2,727,273	8 / 10
2026-10-13	$-2.29	$2,727,273	8 / 10
2026-10-14	$-2.29	$2,727,273	8 / 10
2026-10-15	$-2.29	$2,727,273	8 / 10
2026-10-16	$-2.29	$2,727,273	8 / 10
2026-10-17	$-2.29	$2,727,273	8 / 10
2026-10-18	$-2.29	$2,727,273	8 / 10
2026-10-19	$-2.29	$2,727,273	8 / 10
2026-10-20	$-2.29	$2,727,273	8 / 10
2026-10-21	$-2.29	$2,727,273	8 / 10
2026-10-22	$-2.29	$2,727,273	8 / 10
2026-10-23	$-2.29	$2,727,273	8 / 10
2026-10-24	$-2.29	$2,727,273	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	1	1
2026-06-01	9	1	1
2026-07-01	9	1	1
2026-08-01	9	10	1
2026-09-01	2	10	0
2026-10-01	2	10	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 10 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway to fund operations into 2028Direct metric needs a verified mapping
Manage operating losses and cash burnPublished status: Under Pressure
Advance pipeline toward revenue generationRevenue: $0

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-93.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sionna Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is on watch: clinical programs are progressing, while recent financial performance is weak and the evidence snapshot has low overall confidence.

What's priced into Sionna Therapeutics, Inc.

The snapshot gives no valuation multiple or clear evidence about what investors already expect, so valuation and the expectations gap are difficult to assess. No fragility gates fired, but that does not establish that the business is inexpensive or that expectations are low.

What the fundamentals likely do

Near term, a next-quarter earnings miss is an elevated risk, and further cash declines or rising losses could keep pressure on the operating picture. Over the multi-year view, management has completed Phase 2a enrollment and says cash can fund operations into 2028, but the cash balance has declined and the workforce reduction signals active cost control amid growing losses.

What Sionna Therapeutics, Inc. hinges on

The thesis depends on delivering the planned clinical milestones and maintaining enough cash runway while controlling operating losses. Near term, guidance cuts or weaker jobs data could add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.